Eli Lilly and Company announced detailed results from REVEL, a global Phase III study of CYRAMZA in combination with chemotherapy in patients with second-line non-small cell lung cancer. Data from the trial were published in The Lancet and also presented at the American Society of Clinical Oncology Annual Meeting. REVEL is the first positive Phase III study of a biologic in combination with chemotherapy to demonstrate improved overall survival compared to chemotherapy alone in second-line NSCLC. "While there have been other recent Phase III studies that have evaluated the addition of a cytotoxic or targeted agent in previously-treated NSCLC patient populations, none have demonstrated improved overall survival in the total patient population," said Richard Gaynor, M.D., senior vice president, product development and medical affairs for Lilly Oncology. "We are pleased that CYRAMZA demonstrated a significant survival improvement in a difficult-to-treat patient population where there continues to be a major unmet medical need in both nonsquamous and squamous NSCLC patients. These data build on Lilly's continued commitment to discovering potential new treatment options for the large numbers of people fighting lung cancer. They also add to our growing clinical data set for CYRAMZA, which is being studied in multiple tumor types."